The bio:cap initiative aims to enhance collaboration within Europe's fragmented life sciences ecosystem.
Europe has a rich history in scientific research, bolstered by esteemed institutions and a skilled workforce. Despite significant investments—€3.6 billion in biotech in 2025 and €4.3 billion in drug discovery—the life sciences sector faces challenges due to fragmentation. Lara Formichella, project lead for bio:cap, emphasizes that researchers, investors, and industry leaders often operate in silos, impeding collaboration and timely engagement.
Formichella envisions bio:cap as a platform to unite diverse stakeholders—CEOs, founders, investors, and researchers—to foster earlier interactions. She notes that while the U.S. life sciences ecosystem thrives on dense networks and streamlined commercialization pathways, Europe struggles with regulatory and market access fragmentation. To counter this, bio:cap seeks to encourage informal discussions and curated matchmaking, allowing for significant connections before formal fundraising efforts.
Moreover, bio:cap aims to bridge the gap between academic excellence and commercialization, promoting entrepreneurship as an extension of scientific impact. By bringing together institutions like Charité and the Berlin Institute of Health, the initiative aspires to cultivate trust and collaboration, ultimately enhancing patient outcomes through innovative solutions.
Success for bio:cap will be measured not just by the event itself, but by the partnerships and collaborations it sparks. Formichella believes that fostering connections across science, AI, and capital can create a more unified European life sciences landscape. While acknowledging that bio:cap cannot resolve all systemic issues, she remains hopeful about its potential to catalyze meaningful change within the ecosystem.